The Korean Disease Service, the 26th, announces the progress of the vaccination plan for the elderly
Recommended for local vaccinations under the age of 65 in some European countries such as Germany
65 years old ↑ Results of AZ clinical trial with 30,000 people released at the end of next month
viewer
Through the’Corona 19 Vaccination Implementation Plan’, the Korea Centers for Disease Control and Prevention will enter into vaccinations for about 776,900 people including nursing hospitals and nursing facility residents in the first quarter.
The target of this AstraZeneca product is expected to be the elderly living in nursing hospitals or nursing facilities.
However, controversy is expected to continue over the inoculation of the AstraZeneca vaccine to the elderly.
In fact, the Ministry of Food and Drug Safety said that the AstraZeneca vaccine can be used by all 18 years of age or older on this day, but stated that’the use for the elderly over 65 must be carefully determined’ in the precautions for use did not relieve concerns. In the case of the AstraZeneca vaccine, there is no problem in terms of safety and immune response, but there are only 660 clinical participants to confirm the preventive effect in the elderly, so statistically significant results have not been obtained. In Europe, on the 29th of last month, the European Commission officially approved the conditional sale of the AstraZeneca vaccine, but Germany and France recommended vaccination only for those under the age of 65 because there are insufficient data on vaccine efficacy for the elderly. I have a bar. Belgium lowered the age of those who were vaccinated to under 55. Although not a member of the EU, the Swiss government has suspended approval for the AstraZeneca vaccine and demanded that additional data be submitted. South Africa (South Africa) also withheld the use of the AstraZeneca vaccine due to its limited effectiveness against the mutant virus.
viewer
Even in the medical community, opinions about the AstraZeneca vaccination for the elderly are divided. Prior to this approval, the Ministry of Food and Drug Safety held a verification advisory group and a central pharmacist review committee to gather expert opinions. At the verification advisory group meeting, there were many opinions that AstraZeneca vaccine can be given to elderly 65-year-olds, but the second-stage Central Pharmacy Deliberation Committee retained its judgment and found that the data was insufficient. Advised to discuss.
Accordingly, the Ministry of Food and Drug Safety has placed conditions to submit additional clinical trial results while permitting the vaccine. AstraZeneca is currently undergoing a clinical trial of 30,000 people over the age of 65, and the results are expected to be released by the end of next month.
/ Reporter Park Woo-in [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >